Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for LDL reduction after acute myocardial infarction
IRCT20251211068286N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ranolazine in myocardial infarction (MI) (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoint: Blood LDL levels. Started Jan 2026; status: completed.
02
Drugs
ranolazine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20251211068286N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251211068286N1.